Universität zu Köln

Brueck, Carolin, Golumba-Nagy, Viktoria, Yan, Shuaifeng, Esser, Ruth L., Thiele, Jan, Stahl, David, Pesch, Carola tho, Steinbach-Knoedgen, Eva and Kofler, David M. (2022). Th1 and Th17 cells are resistant towards T cell activation-induced downregulation of CD6. Clin. Immunol., 238. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE. ISSN 1521-7035

Full text not available from this repository.

Abstract

Background: The cell surface molecule CD6 is a modulator of T cell receptor (TCR) signaling. Recently, it has been reported that CD6 is downregulated on CD4+ T cells following T cell activation. This mechanism could limit the efficacy of anti-CD6 therapeutical antibodies. Methods: We analyzed CD6 expression on activated and non-activated Th1 cells and Th17 cells by flow cytometry. Results: Our experiments confirmed a significant downregulation of CD6 on IFN gamma- and IL17-negative CD4+ T cells from healthy individuals and from patients with rheumatoid arthritis following T cell activation with anti-CD3 and anti-CD28 antibodies. In contrast, CD6 expression remained stable on activated Th17 cells and Th1 cells. Conclusions: Th1 and Th17 cells are resistant towards T cell activation-induced downregulation of CD6. These findings are relevant for the future development of CD6 targeting therapies and show that CD6 expression is differentially regulated in CD4+ T cell subsets.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Brueck, Carolin UNSPECIFIED UNSPECIFIED UNSPECIFIED Golumba-Nagy, Viktoria UNSPECIFIED UNSPECIFIED UNSPECIFIED Yan, Shuaifeng UNSPECIFIED UNSPECIFIED UNSPECIFIED Esser, Ruth L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thiele, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Stahl, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Pesch, Carola tho UNSPECIFIED UNSPECIFIED UNSPECIFIED Steinbach-Knoedgen, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Kofler, David M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-662406
DOI:	10.1016/j.clim.2022.109025
Journal or Publication Title:	Clin. Immunol.
Volume:	238
Date:	2022
Publisher:	ACADEMIC PRESS INC ELSEVIER SCIENCE
Place of Publication:	SAN DIEGO
ISSN:	1521-7035
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTI-CD6 MONOCLONAL-ANTIBODY; OPEN-LABEL; TRANSCRIPTION FACTORS; ITOLIZUMAB; EFFICACY; SAFETY; PSORIASIS; RECEPTOR; MODERATE; PHASE-2 Multiple languages Immunology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66240